Anticonvulsant properties of N-(4-methylpiperazin-1-yl)- and N-[3-(4-methylpiperazin-1-yl)-propyl] derivatives of 3-aryl- and 3-spirocycloalkyl-pyrrolidine-2,5-dione

Pharmacological Reports

Volumn 57, Issue 2, 2005, Pages 170-175

  Obniska, Jolanta ^a   Jurczyk, Sławomir ^a   Zejc, Alfred ^a   Kamiński, Krzysztof ^a   Tatarczyńska, Ewa ^b   Stachowicz, Katarzyna ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

3 arylpyrrolidine 2,5 diones; 3 spirocycloalkylpyrrolidine 2,5 diones; 4 methylpiperazine derivatives; Anticonvulsant activity

Indexed keywords

ANTICONVULSIVE AGENT; AROMATIC COMPOUND; CHLORINE; PENTETRAZOLE; PIPERAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; VALPROATE MAGNESIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; ATOM; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRIC SHOCK; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; QUANTITATIVE ANALYSIS; SEIZURE; SEIZURE THRESHOLD; STRUCTURE ANALYSIS;

EID: 20344386468     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Alexander MS, Stables JP, Ciechanowicz-Rutkowska M, Hursthouse MB, Hibbs DE, Edafiogho IO, Moore VA et al.: Spirane 6. Ring A homologues of N-benzyloxy-2-azaspiro[4.4]nonane-1,3-dione. Eur J Med Chem, 1996, 31, 787-795.
2. Brodie MJ: Do we need any more new antiepileptic drugs? Epilepsy Res, 2001, 45, 3-6.
3. Edafiogho IO, Scott KR, Moore JA, Farrar VA, Nicholson JM: Synthesis and anticonvulsant activity of imidooxy derivatives. J Med Chem, 1991, 34, 387-392.
4. Estrada E, Pena A: In silico studies for the rational discovery of anticonvulsant compounds. Bioorg Med Chem, 2000, 8, 2755-2770.
5. Gladding GD, Kupferberg HJ, Swinyard EA: Handbook of Experimental Pharmacology, Antiepileptic Drugs, Springer, Berlin, Tokyo, 1985.
6. Heinecke K, Thiel W: Identity and physicochemical properties of 1-(4-chlorophenyl)-4-morpholinoimidazolin-2-one, AWD 131-138. Pharmazie, 2001, 56, 458-461.
7. Joshi H, Upadhyay P, Karia D, Baxi AJ: Synthesis of some novel imidazolinones as potent anticonvulsant agents. Eur J Med Chem, 2003, 38, 837-840.
8. Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyar E A: Antiepileptic drug development. II. Anticonvulsant drug screening. Epilepsia, 1978, 19, 400-428.
9. Kulak W, Sobaniec W, Wojak K, Czuczwar SJ: Calcium modulation in epilepsy. Pol J Pharmacol, 2004, 56, 29-41.
10. Kupferberg HJ: Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia, 1989, 30, Suppl, 51-56.
11. Litchfield LT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
12. Małek R, Borowicz KK, Kimber-Trojnar Z, Sobieszek G, Piskorska B, Czuczwar SJ: Racemide - a novel potential antiepileptic drug. Pol J Pharmacol, 2003, 55, 691-698.
13. 1 α-phenyl-succinimide. J Am Chem Soc, 1951, 73, 4895-4898.
14. Obniska J, Kulig K, Zejc A: Synthesis and anticonvulsant properties of new N-piperazinylalkyl imides of succinic acid. Acta Pol Pharm-Drug Res, 1998, 55, 223-231.
15. Obniska J, Zagórska A: Synthesis and anticonvulsant properties of new N-[(4-arylpiperazin-1-yl)-methyl] derivatives of 3-aryl pyrrolidine-2,5-dione and 2-azaspiro[4.4]nonane-1,3-dione. Farmaco, 2003, 58, 1227-1234.
16. Ohniska J, Zejc A, Karolak-Wojciechowska J: Synthesis, physicochemical and anticonvulsant properties of new N-pyridyl derivatives of 3-phenyl- and 3,3-diphenyl-succinimides. Farmaco, 1999, 54, 423-429.
17. Obniska J, Zejc A, Zagórska A: Synthesis and anticonvulsant properties of new 1-phenyl and 1-phenylamino-3-phenylpyrrolidine-2,5-dione derivatives. Acta Pol Pharm-Drug Res, 2002, 59, 209-213.
18. Perruca E: The new generation of antiepileptic drugs: advantage and disadvantage. Br J Clin Pharmacol, 1996, 42, 531-543.
19. Perucca E, Kupferberg HJ: Drugs in development. Drugs in early clinical development. In: Antiepileptic Drugs, 5th edn. Eds. Levy RH, Mattson RH, Meldrum BS, Perucca E, Lippincott Williams and Wilkins, Philadelphia, 2002, 915-918.
20. Scott KR, Edafiogho IO, Moore JA, Nicholson JM: Synthesis and anticonvulsant activity of a spirosuccinimide. Pharmacy World J, 1991, 8, 44-50.
21. Scott KR, Moore JA, Zalucky TB, Nicholson JM, Lee JA, Hinko CN: Spiro[4,5] and spiro[4,6] carboxylic acids: cyclic analogues of valproic acid. Synthesis and anticonvulsant evaluation. J Med Chem, 1985, 28, 413-417.
22. Swinyard BA, Brown WC, Goodman LS: Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther, 1952, 106, 319-330.
23. Tarver ML, Nicholson JM, Scott KR: Spirosuccinimides as potential anticonvulsant. J Pharmacol Sci, 1985, 74, 785-787.
24. Unverfert K, Engel J, Hofgen N, Rostock A, Gunter R, Lankau HJ, Menzer M et al.: Synthesis, anticonvulsant activity, and structure-activity relationships of sodium channel bloking 3-aminopyrroles. J Med Chem, 1998, 41, 63-73.
25. White HS, Woodhead JH, Franklin MR: General principles: experimental selection, quantification and evolution of antiepileptic drugs. In: Antiepileptic Drugs 4th edn. Eds. Levy R, Mattson B, Meldrum S, Raven Presss, New York, 1995, 99-110.
26. Zejc A, Obniska J: N-piperazinyl and piperazinylpropyl imides of phenyl and chlorophenyl succinic acids. Acta Pol Pharm, 1984, 41, 529-533.
27. Zejc A, Obniska J, Chojnacka-Wójcik E, Tatarczyńska E, Wiczyńska B: Synthesis and anticonvulsant properties of N-methylpyridyl derivatives of m- and p-bromophenyl-succinimides. Pol J Pharmacol Pharm, 1987, 39, 91-95.